Menopause and Cholesterol: Why Your LDL Rises After 45

Cholesterol rises in menopause because estrogen regulates how efficiently your liver pulls LDL cholesterol out of the bloodstream, and when estrogen falls, that clearance slows.

The mechanism runs through LDL receptors on liver cells. These receptors act like docking ports that capture circulating LDL particles and remove them from the blood. Estrogen increases the expression of these receptors. Less estrogen means fewer receptors, which means LDL particles stay in circulation longer, which means your measured LDL goes up — without you eating a single additional gram of saturated fat.

This is why so many women get a confusing lipid result in their late forties or early fifties. Nothing about their diet changed. Their weight may be stable. They may be exercising more than they did at 35. And the number went up anyway.

Estrogen also influences hepatic lipase and other enzymes involved in lipoprotein processing, and it affects the size and density distribution of LDL particles — a point we will return to, because particle characteristics matter more than the headline number.

The important framing: this is a physiological consequence of the transition, not a report card on your behaviour. Women routinely receive lipid results in midlife accompanied by advice to eat better and move more, when they were already doing both. That advice is not wrong — lifestyle still matters — but it is incomplete, and it misattributes the cause.

What it does mean is that midlife is the right moment to take cardiovascular risk seriously, alongside the other changes happening in the same window, such as [rising blood pressure in menopause](/blog/menopause-blood-pressure-why-it-rises-and-what-helps).

The Study of Women's Health Across the Nation (SWAN) produced the clearest answer to a question that had been genuinely contested: is midlife lipid change caused by menopause, or is it just what happens as people get older?

The key paper — Matthews KA et al., "Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition?", JACC 2009 — followed a multiethnic cohort prospectively and looked specifically at whether risk factor changes were concentrated around the final menstrual period (FMP) rather than spread evenly across the years.

The finding was clean. Of all the risk factors examined, only total cholesterol, LDL cholesterol, and apolipoprotein B showed increases concentrated in the one-year interval before and after the final menstrual period. Other cardiovascular risk factors — blood pressure, insulin, glucose — followed a pattern more consistent with chronological ageing.

In other words: the lipid change has a menopause signature. It is time-locked to your last period, not to your birthday.

The second detail matters just as much. After that spike, LDL levels remain high but do not keep climbing. It is a step change, not a ramp. That has a practical implication: the year either side of your final period is a specific window in which your cardiovascular risk profile is being reset, and it is a sensible moment to get measured and act.

SWAN, which enrolled women aged 42–52 across multiple sites and racial and ethnic groups, remains the reference dataset for what actually happens to women's cardiovascular risk in midlife — precisely because it was designed to disentangle menopause from age.

HDL is where the story gets more interesting, and where the standard lipid panel becomes misleading.

The conventional framing is that HDL is "good cholesterol" and more is better. Through menopause, HDL quantity often stays stable or even rises slightly — which looks reassuring on a results printout.

But research from the SWAN HDL ancillary study suggests the reassurance is partly false. Published work in JACC: Advances examined HDL's cardioprotective function — its actual ability to remove cholesterol from artery walls and carry it to the liver — and found that this function deteriorates as women transition through menopause, even where the measured HDL number does not fall.

This is a meaningful distinction. HDL is not a substance so much as a family of particles doing a job. Menopause appears to change how well they do that job, independent of how many of them there are. A woman can therefore have a perfectly acceptable HDL figure and reduced actual protection.

The same ancillary work has examined LDL subclasses — the size and density of LDL particles — over the menopause transition and linked those changes to coronary calcification and carotid atherosclerosis. Small, dense LDL particles are more atherogenic than large buoyant ones, and the transition shifts the distribution unfavourably.

The practical takeaway: standard cholesterol panels understate what is changing. If your results look borderline and you want a better picture, apolipoprotein B (apoB) is the single most useful additional test — it counts atherogenic particles directly rather than estimating cholesterol content, and it was one of the markers SWAN found rising around the final period.

HRT does affect lipids, and the direction depends substantially on how you take it.

Oral estrogen passes through the liver before reaching the general circulation — the first-pass effect. Because the liver is where lipoprotein metabolism happens, oral estrogen tends to lower LDL and raise HDL. It also tends to raise triglycerides, which is a genuine consideration for women whose triglycerides are already high.

Transdermal estrogen — patches, gels, sprays — bypasses that first pass. It has a more neutral effect on lipids and does not raise triglycerides, which is one reason it is often preferred for women with existing metabolic risk factors. It also carries a lower venous thromboembolism risk than oral preparations.

The critical caveat: HRT is not prescribed as a cholesterol treatment or for cardiovascular prevention. Major guidelines are explicit on this. Lipid effects are a side effect of HRT, not an indication for it. If your reason for considering HRT is symptom relief — hot flashes, night sweats, sleep disruption, genitourinary symptoms — then lipid effects are a factor in choosing the route, not a reason to start.

There is a timing nuance worth knowing. The timing hypothesis — supported by analyses of the Women's Health Initiative and by the KEEPS trial — suggests cardiovascular outcomes on HRT differ depending on whether treatment starts near menopause or many years afterwards. This remains an area of active debate rather than settled fact.

If you are weighing HRT more broadly, our guides on [what the WHI data actually shows about HRT and breast cancer risk](/blog/hrt-and-breast-cancer-risk-what-the-whi-data-actually-shows) and [how long you can stay on HRT](/blog/how-long-can-you-stay-on-hrt-duration-explained) cover the decision in more depth.

The interventions with the strongest evidence are unglamorous and mostly dietary — but the effect sizes are real.

Soluble fibre. Oats, barley, beans, lentils, psyllium, apples. Soluble fibre binds bile acids in the gut, forcing the liver to pull cholesterol from circulation to make more. Psyllium in particular has consistent trial evidence for LDL reduction. This is also the intervention most women in midlife are furthest from meeting.

Replacing saturated fat with unsaturated fat. Not simply cutting fat — swapping it. Olive oil, nuts, seeds, oily fish in place of butter, processed meat, and pastry. The substitution matters more than the reduction.

Plant sterols and stanols. Found in fortified spreads and available as supplements; they compete with cholesterol for absorption in the gut and produce a modest but reproducible LDL reduction.

Resistance training and aerobic exercise. Effects on LDL specifically are modest, but the effects on visceral fat, insulin sensitivity, and overall cardiovascular risk are substantial. Given that muscle preservation is separately urgent after menopause, this is a high-return investment regardless of what it does to one number.

Alcohol reduction. Alcohol drives triglycerides directly and its effects change in midlife — [alcohol and menopause](/blog/alcohol-and-menopause-why-one-glass-hits-harder-after-45) covers why the same glass lands differently after 45.

Statins, when indicated. If your calculated cardiovascular risk warrants it, statins remain the most effective LDL-lowering intervention available, and midlife women have historically been under-treated relative to their actual risk. Being female is not protective after menopause — a misconception that costs lives.

While you are addressing bone and heart health together, [calcium and vitamin D for menopause](/blog/calcium-and-vitamin-d-for-menopause-how-much-you-need) covers the other half of the midlife prevention picture.

Get a lipid panel around the time of your final menstrual period, because that is precisely when SWAN found the change concentrated — and then again a year or two later to see where you have settled.

More specifically:

In perimenopause (mid-40s onward): Establish a baseline if you do not have one. You want to know where you started before the transition moves you.

Within a year of your final period: This is the highest-value single test. SWAN's finding was that the change clusters in this window.

One to two years afterwards: Confirm where your new steady state is. Remember that LDL tends to plateau at the higher level rather than continuing to climb.

Then per your clinician's risk assessment, which should factor in blood pressure, family history, smoking, diabetes, and overall risk score rather than a single lipid value in isolation.

What to ask for. A standard lipid panel gives total cholesterol, LDL, HDL, and triglycerides. Ask additionally for apolipoprotein B if you can get it — it is a better measure of atherogenic particle burden and it was among the markers SWAN identified as rising around the final period. Lipoprotein(a) is worth measuring once in a lifetime; it is largely genetically determined and identifies a group at meaningfully higher risk who would otherwise look unremarkable.

One framing point to hold onto. Cardiovascular disease is the leading cause of death in women, and risk climbs sharply after menopause. Yet women are consistently less likely than men to have lipids checked, less likely to be prescribed statins when indicated, and less likely to have chest symptoms investigated promptly. Knowing your numbers in this specific window is one of the highest-return things you can do — and it connects directly to [what changes in stroke risk after 45](/blog/menopause-and-stroke-risk-what-changes-after-45).